DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-8.66%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$419M
AUM Growth
+$419M
(-4.7%)
Cap. Flow
+$1.35M
Cap. Flow
% of AUM
0.32%
Top 10 Holdings %
Top 10 Hldgs %
47.79%
Holding
85
New
13
Increased
17
Reduced
18
Closed
2
Top Buys
| 1 |
AtriCure
ATRC
|
$8.38M |
| 2 |
UroGen Pharma
URGN
|
$7.87M |
| 3 |
Biohaven
BHVN
|
$3.47M |
| 4 |
Alkermes
ALKS
|
$2.91M |
| 5 |
SLRN
ACELYRIN
SLRN
|
$2.17M |
Top Sells
| 1 |
Perspective Therapeutics
CATX
|
$28.6M |
| 2 |
Procept Biorobotics
PRCT
|
$2.5M |
| 3 |
Tandem Diabetes Care
TNDM
|
$2.18M |
| 4 |
Ascendis Pharma
ASND
|
$1.57M |
| 5 |
BioNTech
BNTX
|
$1.57M |
Sector Composition
| 1 | Healthcare | 85.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Mineralys Therapeutics
MLYS
$1.96B
| $1.39M | 0.33% |
119,000
+29,000
| +32% | +$339K |
|
52
Aquestive Therapeutics
AQST
$474M
| $1.38M | 0.33% |
530,000
+30,000
| +6% | +$78K |
|
53
Lineage Cell Therapeutics
LCTX
$279M
| $1.35M | 0.32% |
1,350,708
-15,600
| -1% | -$15.6K |
|
54
Alto Neuroscience
ANRO
$103M
| $1.28M | 0.31% |
120,000
+110,000
| +1,100% | +$1.18M |
|
55
Gossamer Bio
GOSS
$587M
| $1.27M | 0.3% |
1,409,262
| – | – |
|
56
Immunovant
IMVT
$2.68B
| $1.26M | 0.3% |
47,916
+18,500
| +63% | +$488K |
|
|
SAGE
57
DELISTED
Sage Therapeutics
SAGE
| $1.26M | 0.3% |
+116,200
| New | +$1.26M |
|
|
AUTL
58
Autolus Therapeutics
AUTL
$394M
| $1.21M | 0.29% |
346,667
+130,000
| +60% | +$452K |
|
|
CNTA
59
Centessa Pharmaceuticals
CNTA
$2.13B
| $1.11M | 0.27% |
+122,882
| New | +$1.11M |
|
60
Tourmaline Bio
TRML
$619M
| $977K | 0.23% |
+75,982
| New | +$977K |
|
61
Sutro Biopharma
STRO
$82.8M
| $966K | 0.23% |
329,579
-4,500
| -1% | -$13.2K |
|
|
62
Procept Biorobotics
PRCT
$2.15B
| $855K | 0.2% |
13,994
-41,001
| -75% | -$2.5M |
|
63
PolyPid
PYPD
$54.7M
| $795K | 0.19% |
184,846
-600
| -0.3% | -$2.58K |
|
64
Compugen
CGEN
$134M
| $776K | 0.19% |
462,202
+32,000
| +7% | +$53.8K |
|
|
NYXH
65
Nyxoah
NYXH
$230M
| $754K | 0.18% |
+108,108
| New | +$754K |
|
66
Adicet Bio
ACET
$60.9M
| $726K | 0.17% |
600,000
| – | – |
|
67
Acrivon Therapeutics
ACRV
$43.1M
| $704K | 0.17% |
121,351
-10,000
| -8% | -$58K |
|
|
SYRS
68
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $701K | 0.17% |
135,850
| – | – |
|
69
ADC Therapeutics
ADCT
$355M
| $645K | 0.15% |
+204,081
| New | +$645K |
|
70
Terns Pharmaceuticals
TERN
$647M
| $586K | 0.14% |
+86,000
| New | +$586K |
|
71
Neuronetics
STIM
$210M
| $565K | 0.13% |
313,717
| – | – |
|
72
Aprea Therapeutics
APRE
$9.03M
| $558K | 0.13% |
137,174
| – | – |
|
73
Neurogene
NGNE
$277M
| $400K | 0.1% |
+11,000
| New | +$400K |
|
74
Masimo
MASI
$7.4B
| $378K | 0.09% |
3,000
| – | – |
|
|
ADAP
75
Adaptimmune Therapeutics
ADAP
$14.5M
| $333K | 0.08% |
341,064
| – | – |
|